Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers

References

• CoccoS, PiezzoM, CalabreseA, et al. Biomarkers in triple-negative breast cancer: state-of-The-art and future perspectives. Int J Mol Sci. 2020;21(13):4579. doi:10.3390/ijms21134579
   Web of Science ®Google Scholar
• SiegelRL, MillerKD, JemalA. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• RiegerMA, EbnerR, BellDR, et al. Identification of a novel mammary-restricted cytochrome p450, cyp4z1, with overexpression in breast carcinoma. Cancer Res. 2004;64(7):2357–2364. doi:10.1158/0008-5472.can-03-084915059886
   PubMed Web of Science ®Google Scholar
• YangX, HutterM, GohWWB, BureikM. Cyp4z1 - a human cytochrome p450 enzyme that might hold the key to curing breast cancer. Curr Pharm Des. 2017;23(14):2060–2064. doi:10.2174/138161282366617020715015628176668
   PubMed Web of Science ®Google Scholar
• TradonskyA, RubinT, BeckR, RingB, SeitzR, MairS. A search for reliable molecular markers of prognosis in prostate cancer: a study of 240 cases. Am J Clin Pathol. 2012;137(6):918–930. doi:10.1309/AJCPF3QWIG8FWXIH22586051
   PubMed Web of Science ®Google Scholar
• DownieD, McFadyenMC, RooneyPH, et al. Profiling cytochrome p450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res. 2005;11(20):7369–7375. doi:10.1158/1078-0432.CCR-05-046616243809
   PubMed Web of Science ®Google Scholar
• MurrayGI, PatimallaS, StewartKN, MillerID, HeysSD. Profiling the expression of cytochrome p450 in breast cancer. Histopathology. 2009;57(2):202–211. doi:10.1111/j.1365-2559.2010.03606.x
   Web of Science ®Google Scholar
• Al-SarairehYM, AlboaisaNS, AlrawashdehHM, et al. Screening of cytochrome 4z1 expression in human non-neoplastic, pre-neoplastic and neoplastic tissues. Ecancermedicalscience. 2020;14:1114. doi:10.3332/ecancer.2020.111433144882
   PubMed Web of Science ®Google Scholar
• Al-SarairehYM, AlshammariFO, YoussefAM, et al. Profiling of cyp4z1 and cyp1b1 expression in bladder cancers. Sci Rep. 2021;11(1):1–8. doi:10.1038/s41598-021-85188-433414495
   PubMed Web of Science ®Google Scholar
• YuW, ChaiH, LiY, et al. Increased expression of cyp4z1 promotes tumor angiogenesis and growth in human breast cancer. Toxicol Appl Pharmacol. 2012;264(1):73–83. doi:10.1016/j.taap.2012.07.01922841774
   PubMed Web of Science ®Google Scholar
• Al-sarairehYM, AlshammariFOFO, YoussefAMM, et al. Cytochrome 4z1 expression is correlated with poor prognosis in patients with cervical cancer. Curr Oncol. 2021;28(5):3573–3584.34590601
   PubMed Web of Science ®Google Scholar
• Khayeka-WandabwaC, MaX, CaoX, et al. Plasma membrane localization of cyp4z1 and cyp19a1 and the detection of anti-cyp19a1 autoantibodies in humans. Int Immunopharmacol. 2019;73:64–71. doi:10.1016/j.intimp.2019.05.00331082724
   PubMed Web of Science ®Google Scholar
• NunnaV, JalalN, BureikM. Anti-cyp4z1 autoantibodies detected in breast cancer patients. Cell Mol Immunol. 2017;14(6):572–574. doi:10.1038/cmi.2017.21.28435160
   PubMed Web of Science ®Google Scholar
• ZollnerA, DraganCA, PistoriusD, et al. Human cyp4z1 catalyzes the in-chain hydroxylation of lauric acid and myristic acid. Biol Chem. 2009;390(4):313–317. doi:10.1515/BC.2009.03019090726
   PubMed Web of Science ®Google Scholar
• McDonaldMG, RayS, AmorosiCJ, et al. Expression and functional characterization of breast cancer-associated cytochrome p450 4z1 in saccharomyces cerevisiae. Drug Metab Dispos. 2017;45(12):1364–1371. doi:10.1124/dmd.117.07818829018033
   PubMed Web of Science ®Google Scholar
• PanigrahyD, GreeneER, PozziA, WangDW, ZeldinDC. Eet signaling in cancer. Cancer Metastasis Rev. 2011;30(3–4):525–540. doi:10.1007/s10555-011-9315-y22009066
   PubMed Web of Science ®Google Scholar
• LuoJ, Feng-X-X, LuoC, et al. 14,15-eet induces the infiltration and tumor-promoting function of neutrophils to trigger the growth of minimal dormant metastases. Oncotarget. 2016;7(28):43324–43336. doi:10.18632/oncotarget.970927270316
   PubMedGoogle Scholar
• BrunoRD, NjarVCO. Targeting cytochrome p450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem. 2007;15(15):5047–5060. doi:10.1016/j.bmc.2007.05.04617544277
   PubMed Web of Science ®Google Scholar
• FitzgibbonsPL, DillonDA, AlsabehR, et al. Template for reporting results of biomarker testing of specimens from patients with carcinoma of the breast. Arch Pathol Lab Med. 2014;138(5):595–601. doi:10.5858/arpa.2013-0566-CP24236805
   PubMed Web of Science ®Google Scholar
• HarveyJM, ClarkGM, OsborneCK, AllredDC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–1481. doi:10.1200/jco.1999.17.5.147410334533
   PubMed Web of Science ®Google Scholar
• DaltoéRD, MadeiraKP, de CarvalhoAA, de RezendeLC, SilvaIV, RangelLB. Evaluation of the progesterone receptor status in breast cancer using three different antibodies: a comparison by Allred score system. Int J Clin Exp Pathol. 2014;7(1):331–339.24427354
   PubMed Web of Science ®Google Scholar
• AllredDC. Problems and solutions in the evaluation of hormone receptors in breast cancer. J Clin Oncol. 2008;26(15):2433–2435. doi:10.1200/jco.2007.15.780018487563
   PubMed Web of Science ®Google Scholar
• AndersC, CareyLA. Understanding and treating triple-negative breast cancer. Oncology. 2008;22(11):1233–1239;discussion 1239–1240, 1243.
   Web of Science ®Google Scholar
• AlexanianA, MillerB, RomanRJ, SorokinA. 20-hete-producing enzymes are up-regulated in human cancers. Cancer Genom Proteom. 2012;9(4):163–169.
   PubMed Web of Science ®Google Scholar
• ZhengL, LiX, GuY, LvX, XiT. The 3ʹutr of the pseudogene cyp4z2p promotes tumor angiogenesis in breast cancer by acting as a cerna for cyp4z1. Breast Cancer Res Treat. 2015;150(1):105–118. doi:10.1007/s10549-015-3298-225701119
   PubMed Web of Science ®Google Scholar
• ZhengL, LiX, MengX, et al. Competing endogenous RNA networks of cyp4z1 and pseudogene cyp4z2p confer tamoxifen resistance in breast cancer. Mol Cell Endocrinol. 2016;427:133–142. doi:10.1016/j.mce.2016.03.012.26980484
   PubMed Web of Science ®Google Scholar
• LiC, ZhengL, XinY, et al. The competing endogenous RNA network of cyp4z1 and pseudogene cyp4z2p exerts an anti-apoptotic function in breast cancer. FEBS Lett. 2017;591(7):991–1000. doi:10.1002/1873-3468.1260828236635
   PubMed Web of Science ®Google Scholar
• ZhengL, GuoQ, XiangC, et al. Transcriptional factor six2 promotes the competitive endogenous RNA network between cyp4z1 and pseudogene cyp4z2p responsible for maintaining the stemness of breast cancer cells. J Hematol Oncol. 2019;12(1):23. doi:10.1186/s13045-019-0697-630832689
   PubMed Web of Science ®Google Scholar
• YanQ, MachalzD, ZollnerA, SorensenEJ, WolberG, BureikM. Efficient substrate screening and inhibitor testing of human cyp4z1 using permeabilized recombinant fission yeast. Biochem Pharmacol. 2017;146:174–187. doi:10.1016/j.bcp.2017.09.01128951277
   PubMed Web of Science ®Google Scholar
• KowalskiJP, McDonaldMG, PelletierRD, HanenbergH, WiekC, RettieAE. Design and characterization of the first selective and potent mechanism-based inhibitor of cytochrome p450 4z1. J Med Chem. 2020;63(9):4824–4836. doi:10.1021/acs.jmedchem.0c0010132302132
   PubMed Web of Science ®Google Scholar